NEW YORK (GenomeWeb) – Agilent Technologies announced today that the US Food and Drug Administration has approved its Dako PD-L1 IHC 28-8 pharmDx complementary diagnostic for two additional indications: urothelial carcinoma (UC) and squamous cell carcinoma of the head and neck (SCCHN).
To read the full story....
Register for Free....and receive Daily News bulletins.
Already have an account?
Login Now.